Bajaj Healthcare Limited — Important, 19-03-2025: General Updates

Bajaj Healthcare Limited has announced a board meeting to discuss the recommendation received from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets in various strengths. This advanced anti-seizure medication aims to improve treatment options for epilepsy patients in India. The Phase III trials will assess the drug's efficacy and safety, leading to a potential commercial launch upon successful results. This regulatory milestone could enhance the company's growth prospects in the Indian pharmaceutical market, signaling a positive outlook for stakeholders.